Kiniksa Pharmaceuticals Company Insiders

Kiniksa Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.0316) % which means that it has lost $0.0316 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0215) %, meaning that it created substantial loss on money invested by shareholders. Kiniksa Pharmaceuticals' management efficiency ratios could be used to measure how well Kiniksa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Kiniksa Pharmaceuticals' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.03, whereas Return On Capital Employed is forecasted to decline to (0.05). At present, Kiniksa Pharmaceuticals' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 301.9 M, whereas Total Assets are forecasted to decline to about 309.2 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 221.4 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 57.9 M.

Kiniksa Pharmaceuticals Workforce Comparison

Kiniksa Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of (0.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.09) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.09.

Kiniksa Pharmaceuticals Insider Trading History

Kiniksa Pharmaceuticals Notable Stakeholders

The success or failure of an entity such as Kiniksa Pharmaceuticals often depends on how effective the management is. Kiniksa Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kiniksa management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kiniksa management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Kiniksa Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kiniksa Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kiniksa Pharmaceuticals' management manipulating its earnings.

When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.